Hepatitis B virus infection and the dialysis patient

Fabrizio Fabrizi; Piergiorgio Messa; Paul Martin

doi:10.1111/j.1525-139X.2008.00437.x

Hepatitis B virus infection and the dialysis patient

Fabrizio Fabrizi, Piergiorgio Messa, Paul Martin

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Prevention of nosocomial transmission of hepatitis B virus (HBV) has been a signal achievement in the management of chronic kidney disease. The rate of serum hepatitis B surface antigen (HBsAg) seropositivity in patients on maintenance hemodialysis in the developed world is currently low (0-10%) but outbreaks of acute HBV infection continue to occur in this setting. The prevalence of HBV infection within dialysis units in developing countries appears higher (2-20%) based on relatively few reports. Although data are limited, HBV infection in dialysis population diminishes survival; HBV viral load in HBsAg-positive dialysis patients is reportedly low and stable over time. Updated recommendations for the management of HBsAg chronic carriers on maintenance dialysis have been issued. No rigorously controlled treatment trials for treatment of hepatitis B with either interferon or lamivudine therapy in dialysis patients are currently available.

Original language	English
Pages (from-to)	440-446
Number of pages	7
Journal	Seminars in Dialysis
Volume	21
Issue number	5
DOIs	https://doi.org/10.1111/j.1525-139X.2008.00437.x
Publication status	Published - Sept 2008

ASJC Scopus subject areas

Nephrology

Access to Document

10.1111/j.1525-139X.2008.00437.x

Cite this

@article{fe72f24cfb314f669c30aaa5743a787b,

title = "Hepatitis B virus infection and the dialysis patient",

abstract = "Prevention of nosocomial transmission of hepatitis B virus (HBV) has been a signal achievement in the management of chronic kidney disease. The rate of serum hepatitis B surface antigen (HBsAg) seropositivity in patients on maintenance hemodialysis in the developed world is currently low (0-10%) but outbreaks of acute HBV infection continue to occur in this setting. The prevalence of HBV infection within dialysis units in developing countries appears higher (2-20%) based on relatively few reports. Although data are limited, HBV infection in dialysis population diminishes survival; HBV viral load in HBsAg-positive dialysis patients is reportedly low and stable over time. Updated recommendations for the management of HBsAg chronic carriers on maintenance dialysis have been issued. No rigorously controlled treatment trials for treatment of hepatitis B with either interferon or lamivudine therapy in dialysis patients are currently available.",

author = "Fabrizio Fabrizi and Piergiorgio Messa and Paul Martin",

year = "2008",

month = sep,

doi = "10.1111/j.1525-139X.2008.00437.x",

language = "English",

volume = "21",

pages = "440--446",

journal = "Seminars in Dialysis",

issn = "0894-0959",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Hepatitis B virus infection and the dialysis patient

AU - Fabrizi, Fabrizio

AU - Messa, Piergiorgio

AU - Martin, Paul

PY - 2008/9

Y1 - 2008/9

N2 - Prevention of nosocomial transmission of hepatitis B virus (HBV) has been a signal achievement in the management of chronic kidney disease. The rate of serum hepatitis B surface antigen (HBsAg) seropositivity in patients on maintenance hemodialysis in the developed world is currently low (0-10%) but outbreaks of acute HBV infection continue to occur in this setting. The prevalence of HBV infection within dialysis units in developing countries appears higher (2-20%) based on relatively few reports. Although data are limited, HBV infection in dialysis population diminishes survival; HBV viral load in HBsAg-positive dialysis patients is reportedly low and stable over time. Updated recommendations for the management of HBsAg chronic carriers on maintenance dialysis have been issued. No rigorously controlled treatment trials for treatment of hepatitis B with either interferon or lamivudine therapy in dialysis patients are currently available.

AB - Prevention of nosocomial transmission of hepatitis B virus (HBV) has been a signal achievement in the management of chronic kidney disease. The rate of serum hepatitis B surface antigen (HBsAg) seropositivity in patients on maintenance hemodialysis in the developed world is currently low (0-10%) but outbreaks of acute HBV infection continue to occur in this setting. The prevalence of HBV infection within dialysis units in developing countries appears higher (2-20%) based on relatively few reports. Although data are limited, HBV infection in dialysis population diminishes survival; HBV viral load in HBsAg-positive dialysis patients is reportedly low and stable over time. Updated recommendations for the management of HBsAg chronic carriers on maintenance dialysis have been issued. No rigorously controlled treatment trials for treatment of hepatitis B with either interferon or lamivudine therapy in dialysis patients are currently available.

UR - http://www.scopus.com/inward/record.url?scp=54749142825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749142825&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2008.00437.x

DO - 10.1111/j.1525-139X.2008.00437.x

M3 - Article

C2 - 18397202

AN - SCOPUS:54749142825

SN - 0894-0959

VL - 21

SP - 440

EP - 446

JO - Seminars in Dialysis

JF - Seminars in Dialysis

IS - 5

ER -

Hepatitis B virus infection and the dialysis patient

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this